Pfizer/Andrx Cardura XL "approvable"
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Pfizer/Andrx' sustained-release benign prostatic hyperplasia agent Cardura XL (doxazosin) is "approvable" June 18. Pfizer "has informed us that it intends to respond promptly," marketing partner Andrx says June 21. Under a November 2003 deal, Andrx will receive exclusive U.S. distribution rights to Cardura XL upon approval...